SUTRO BIOPHARMA, INC. 4

Daniel H. Petree received a stock option award for 10,000 shares of Sutro Biopharma, Inc. common stock at an exercise price of $26.09 on June 5, 2026.

On June 5, 2026, Daniel H. Petree, an insider of Sutro Biopharma, Inc., received a stock option award to purchase 10,000 shares of the company’s common stock at an exercise price of $26.09 per share, with a 10‑year term expiring June 5, 2036. The option will vest in 8.33% monthly installments starting July 5, 2026, and will be fully vested and exercisable by the earlier of the company’s 2027 annual stockholders meeting or June 5, 2027, contingent on continued service. This is a routine equity compensation grant and does not represent an open‑market purchase or sale of shares; following the grant, Petree holds derivative rights over 10,000 shares, but no post‑transaction aggregate value can be precisely determined from the filing in the absence of a current market price.

Filing Facts

CIK

1382101

Ticker

STRO

Form

4

Source Type

sec

Accession

0001294939-26-000002

Alert Tier

5